Elephas introduced an AI Avatar that quickly walks through the ASCO2026 poster showing 93% concordance between a cancer patient's clinical response on immunotherapy and the Functional Precision Medicine platform's predicted response.
Public source
Publisher name
Public post
Introducing my AI Avatar, that (or is it "who"?) quickly walks you through our recent #ASCO2026 poster, showing 93% concordance between a cancer patient's clinical respo…
Company
Elephas
Live tumor profiling for immunotherapy response prediction
- Industry
- Biotechnology Research
- Location
- Madison, US
- Company size
- 51–200 employees
About Elephas
Elephas has developed an ex-vivo platform to assess how live patient biopsies respond to immunotherapies. By preserving the native tumor microenvironment from a live core needle biopsy and using a novel method to address tumor heterogeneity, the elive™ platform enables a real-time characterization of immune response. To learn more, visit www.elephas.com
See moreLatest activity
Latest activity from Elephas
3 signals
Products & Services
Elephas launched elive, a platform designed to assess real immune behavior in live tumor biopsies beyond current predictive biomarkers.
Research & Knowledge
Elephas presented new data on the elive™ index, a classifier of ex vivo immune checkpoint inhibitor (ICI) response built from live tumor fragments at ASCO26.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
SOPHiA GENETICS
SOPHiA GENETICS published exploratory research in Clinical Cancer Research examining how integrated analysis of clinical, genomic, and biomarker data supports understanding of patient heterogeneity in advanced solid tumors treated with combination immunotherapy.
Research & Knowledge
1Cell.Ai Inc.
1Cell.Ai Inc. published a study in Cancer Research, an AACR Journals, highlighting the potential of comprehensive ctDNA profiling in treatment-naïve patients with early-stage breast cancer.
Research & Knowledge
Cure51
Cure51 published a Rosalind Study combining multiple layers of patient data, including genomics, transcriptomics, pathology, clinical history, and multi-omics insights, to integrate complex datasets and identify patterns for AI-driven treatment prediction.
Research & Knowledge
Concr
Concr published a study in Frontiers showing that FarrSight predicts chemotherapy response in pancreatic cancer better than conventional biomarkers.
Research & Knowledge
Alithea Bio